Neuron cells system
Neuron cells system
Healthcare Professionals Support
We help healthcare professionals serve patients, exchange scientific knowledge, and share trusted educational materials locally.
How We Interact With Healthcare Professionals
We foster relationships with healthcare professionals (HCPs) to share up-to-date information about our products, exchange scientific and medical insights, and disseminate educational information that could help patients better understand and manage their conditions.
To ensure these interactions are relevant, meet the highest ethical standards, and comply with international and regional regulations, the focus of this work is local.
Financial Transparency at Sanofi: Building Trust Through Openness
Our Commitment to Transparency
At Sanofi, transparency in our relationships with healthcare professionals (HCPs) and healthcare organizations (HCOs) is fundamental to maintaining trust and integrity. This openness ensures that medical decisions remain independent and patient-focused, reinforcing confidence that treatment decisions are based solely on medical evidence and patient benefit.
The Self Certification Letter affirms Sanofi’s commitment to the principles of the EFPIA Code of Practice.
Disclosure reports by country
To download or access the market-level disclosure reports, please click on the country links below.
Eurasia
- Austria
- Belgium
- Czech Republic
- Denmark
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Luxembourg
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Russia
- Spain
- Sweden
- Switzerland
- Turkey : According to local regulation the report is not publicly available. Further information can be found on: https://www.aifd.org.tr/
- Ukraine
- United Kingdom
International
- Australia : According to local code of practice the report is not publicaly available. However it is possible to find more information about transparency and Medicines Australia in the Medicines Australia webpage. Link (https://www.medicinesaustralia.com.au/)
- Brazil (Minas Gerais)
- Chile : According to local code of practice the report is not publicaly available. However it is possible to find more information about Transparency and Cámara de La Innovación Farmacéutica in CIF webpage. Link (https://cifchile.cl/)
- Colombia : According to local regulation the report is not publicaly available. However it is possible to find more information about transparency and Colombia Ministerio de La Salud, on its website. Link: https://normograma.supersalud.gov.co/index.html
- India : According to local regulation the report is not publicly available. However, it is possible to find more information about transparency reporting in India on OPPI on its website: www.indiaoppi.com/ucpmp/
- Israel
- Japan
- Mexico : According to local code of practice the report is not publicaly available. However it is possible to find more information about transparency and in Cetifarma on its webpage. Link https://www.cetifarma.org.mx/
- Philippines : According to local regulation the report is not publicaly available. However it is possible to find more information about transparency and Philippiness FDA on its website. Link: https://www.fda.gov.ph/
- Saudi Arabia: According to local regulation the report is not publicaly available. However it is possible to find more information about transparency and SFDA on its website. Link: https://www.sfda.gov.sa/en/eservices?keys=Transparency%20and%20Disclosure
- South Korea (MOHW)
- South Korea (KRPIA) : According to local code of practice the report is not publicaly available. However it is possible to find more information about transparency and iKRPIA, on its webpage https://www.krpia.or.kr/
North America
Managed Access Programs (MAPs)
Investigational medicines, that is, medicines for which a marketing authorization application is ongoing or medicinal products which are not yet commercially available, may be used to treat certain people who are affected by life-threatening, long-lasting or seriously debilitating illnesses and are unable to participate in a clinical trial. Under certain circumstances, we make such medicines available to eligible patients.
Post-trial access
Some people may benefit from an investigational product during a clinical trial, but don’t have access to the product once their participation has ended. That might be because it hasn’t been approved, or it is not yet on the market.
Under these circumstances and based on medical need, we may provide “post-trial access” to the experimental product.
Scientific and Medical Contributions
Sanofi supports medical and scientific activities for Health Care Professionals (HCPs) or Scientific Experts, provided there is no direct return for Sanofi. Sanofi must have no influence on the development, organization, content, or faculty selection of the program.
Humanitarian aid
Through our humanitarian programs for rare diseases and hemophilia, we support people throughout the world who have few or no treatment options.
Clinical Trials: External Sponsored Research
We support bona fide research designed to advance science toward treatments that improve the standard of care. We receive, review, and respond to unsolicited proposals from health care professionals, scientists, and researchers or institutions (i.e. external sponsor) for research support.
Unsolicited proposals may be for Investigator Sponsored Studies (ISS) and Externally Sponsored Collaborations (ESC).